Clinical Research Directory

Inclusion Criteria: * Histological documentation of primary colorectal tumor is available; * 1-3 CRLM visible on ceCT and/or MRI, size 0-5 cm and not eligible for resection or thermal ablation due to location close to a vessel or bile duct; * Additional CRLM are allowed if considered either resectable or ablatable with a maximum of 10 CRLM. In patients with extrahepatic disease, a maximum of 5 additional CRLM is allowed; * No or limited extrahepatic disease (1 extrahepatic lesion is allowed, with some exclusions mentioned in the exclusion criteria); * Prior focal liver treatment is allowed; * Subjects should preferably be treated with neo-adjuvant systemic therapy; * Subjects with recurrent (either local or distant-hepatic) CRLM after previous focal treatment who are unsuitable for (further) systemic therapy (further downsizing or conversion to resectable disease improbable); * Adequate bone marrow, liver and renal function as assessed by laboratory requirements to be conducted within 7 days prior to definite inclusion; * ASA classification 0 - 3; * Age \>18 years; * Written informed consent; Exclusion Criteria: * Radical treatment unfeasible or unsafe (e.g. insufficient FLR); * \>10 CRLM; \>5 CRLM when extra-hepatic disease is present; * Positive para-aortal lymph nodes, celiac lymph nodes, adrenal metastases, pleural carcinomatosis or peritoneal carcinomatosis; * Subjects who have progressive disease after neo-adjuvant systemic therapy; * History of epilepsy; * History of cardiac disease: * Uncontrolled hypertension. Blood pressure must be ≤160/95 mmHg at the time of screening on a stable antihypertensive regimen; * Compromised liver function (e.g. signs of portal hypertension, INR \> 1,5 without use of anticoagulants, ascites); * Pregnant or breast-feeding subjects; * Immunotherapy ≤ 2 weeks prior to the procedure; * Chemotherapy and/or targeted therapy ≤ 2 weeks prior to the procedure; * Severe allergy to contrast media not controlled with premedication; * Any condition that is unstable or that could jeopardize the safety of the subject and their compliance in the study.